QV Investors Inc. cut its stake in shares of Stryker Corporation (NYSE:SYK) by 23.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 146,604 shares of the medical technology company’s stock after selling 44,700 shares during the period. Stryker accounts for about 1.8% of QV Investors Inc.’s portfolio, making the stock its 20th biggest position. QV Investors Inc.’s holdings in Stryker were worth $22,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of the business. CENTRAL TRUST Co grew its stake in shares of Stryker by 16.6% during the fourth quarter. CENTRAL TRUST Co now owns 11,982 shares of the medical technology company’s stock valued at $1,855,000 after buying an additional 1,710 shares during the last quarter. Strs Ohio grew its stake in shares of Stryker by 15.7% during the fourth quarter. Strs Ohio now owns 536,878 shares of the medical technology company’s stock valued at $83,130,000 after buying an additional 72,903 shares during the last quarter. Cornerstone Investment Partners LLC grew its stake in shares of Stryker by 100.0% during the fourth quarter. Cornerstone Investment Partners LLC now owns 14,998 shares of the medical technology company’s stock valued at $2,322,000 after buying an additional 7,499 shares during the last quarter. State of Alaska Department of Revenue grew its stake in shares of Stryker by 216.4% during the fourth quarter. State of Alaska Department of Revenue now owns 48,095 shares of the medical technology company’s stock valued at $7,445,000 after buying an additional 32,892 shares during the last quarter. Finally, McCollum Christoferson Group LLC bought a new position in shares of Stryker during the fourth quarter valued at approximately $7,221,000. Institutional investors and hedge funds own 74.91% of the company’s stock.
Shares of Stryker Corporation (NYSE:SYK) traded up $1.24 during trading hours on Tuesday, reaching $162.52. The company had a trading volume of 1,354,600 shares, compared to its average volume of 1,246,443. Stryker Corporation has a 52 week low of $119.17 and a 52 week high of $164.20. The company has a market capitalization of $60,760.00, a PE ratio of 34.65, a P/E/G ratio of 2.31 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.02. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The company had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the prior year, the firm earned $1.39 earnings per share. Stryker’s revenue was up 6.1% compared to the same quarter last year. sell-side analysts anticipate that Stryker Corporation will post 6.49 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Investors of record on Friday, December 29th will be paid a $0.47 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.88 annualized dividend and a yield of 1.16%. This is a boost from Stryker’s previous quarterly dividend of $0.43. Stryker’s dividend payout ratio is 40.09%.
A number of research analysts have recently commented on the company. Cowen set a $160.00 target price on Stryker and gave the company a “buy” rating in a research note on Friday, October 6th. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating in a research note on Friday, November 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $163.00 target price on shares of Stryker in a research note on Friday, January 5th. Barclays upped their target price on Stryker from $137.00 to $148.00 and gave the company an “underweight” rating in a research note on Friday, October 27th. Finally, Zacks Investment Research raised Stryker from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $156.60.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the sale, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.40% of the stock is owned by corporate insiders.